MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$243,745
Net Income
-$6,638,260
Net Profit Margin
-2723.44%
EPS
-$0.28
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Collaboration revenue
243,745
251,147
3,959,999
3,564,254
Research and development
5,030,667
4,096,580
4,940,495
2,916,875
In-process research and development
1,656
10,000
1,773,606
515,996
General and administrative
2,255,603
3,781,977
3,269,945
2,557,440
Depreciation
2,807
2,807
6,841
6,840
Total operating expenses
7,290,733
7,891,364
9,990,887
-
Loss from operations
-7,046,988
-7,640,217
-6,030,888
-
Other income
408,728
433,227
325,435
317,066
Pre-tax loss
-6,638,260
-7,206,990
-5,705,453*
-
Income tax (expense) benefit
-
-
3,089*
-
Net loss
-6,638,260
-7,206,990
-5,708,542
-2,115,831
Basic EPS
-0.28
-0.32
-0.341
-0.13
Diluted EPS
-0.28
-0.32
-0.341
-0.13
Basic Average Shares
23,457,227
22,644,304
16,742,821
16,732,766
Diluted Average Shares
23,457,227
22,644,304
16,742,821
16,732,766
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$6,638,260
(-8.91%↓ Y/Y)
Pre-tax loss
-$6,638,260
(-8.91%↓ Y/Y)
Other income
$408,728
(27.91%↑ Y/Y)
Loss from operations
-$7,046,988
(-9.86%↓ Y/Y)
Collaboration revenue
$243,745
(48.97%↑ Y/Y)
Total operating
expenses
$7,290,733
(10.83%↑ Y/Y)
Research and development
$5,030,667
(37.33%↑ Y/Y)
General and
administrative
$2,255,603
(-22.44%↓ Y/Y)
Depreciation
$2,807
(-58.96%↓ Y/Y)
In-process research and
development
$1,656
Buy us a coffee
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)